2,4,5-Triaminoquinazoline | 123242-03-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2,4,5-Triaminoquinazoline
• 英文别名: quinazoline-2,4,5-triamine
• CAS: 123242-03-5
• 化学式: C₈H₉N₅
• 分子量: 175.19
• InChiKey: REUNOXHTPWSRBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] SMALL MOLECULE INHIBITORS OF DIHYDROFOLATE REDUCTASE<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE LA DIHYDROFOLATE RÉDUCTASE
  申请人：CIDARA THERAPEUTICS INC

  公开号：WO2016201219A1

  公开（公告）日：2016-12-15

  The disclosure relates to compositions and methods for the treatment of fungal, bacterial, and parasitic infections and inhibition of fungal, bacterial, and parasitic growth. In particular, such compositions include dihydrofolate reductase (DHFR) inhibitors that are able to bind to DHFR and inhibit its function, resulting in inhibition of DNA biosynthesis and reduced cell division. The disclosure features DHFR inhibitors having a diaminoquinazoline scaffold.

  该披露涉及用于治疗真菌、细菌和寄生虫感染以及抑制真菌、细菌和寄生虫生长的组合物和方法。具体来说，这些组合物包括能够结合到二氢叶酸还原酶（DHFR）并抑制其功能的DHFR抑制剂，从而抑制DNA合成和减少细胞分裂。该披露涉及具有二氨基喹唑啉骨架的DHFR抑制剂。
• Process for preparing 5,6-substituted-2,4-quinazolinediamines and intermediates
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0253396A2

  公开（公告）日：1988-01-20

  An improved process for the preparation of 6-substituted-5-­alkyl-2,4-quinazolinediamines, useful in the production of trimetrexate and similar antifolate agents, together with several novel intermediates are disclosed.

  本发明公开了一种改进的 6-取代-5-烷基-2,4-喹唑啉二胺制备工艺以及几种新型中间体，该工艺可用于生产曲美曲塞特和类似的抗叶酸制剂。
• SYSTEM AND METHOD FOR AUTOMATED PREDICTION OF VULNERABILITIES IN BIOLOGICAL SAMPLES
  申请人：MEMORIAL SLOAN-KETTERING CANCER CENTER

  公开号：US20160117440A1

  公开（公告）日：2016-04-28

  In order to exploit vulnerabilities of cancer cells on the basis of homozygous deletion, a genomic profile of cancer cells in a biological sample is analyzed to identify homozygous deletions of one or more genes. The homozygous deletions, in turn, are analyzed in view of pathway data (e.g., metabolic, signaling, and/or cell-to-cell communication pathway data obtained from one or more databases) to determine a subset of homozygous deletions performing a function important to the viability of the cell. From this subset of homozygous deletions, cellular pathway data is analyzed to identify one or more partner genes (e.g., synthetic lethals) considered to facilitate or perform the same or similar function as the respective homozygous deletion. Drug annotations, in turn, may be reviewed to identify drugs that inhibit at least one of the synthetic lethal genes and/or gene products.